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ABSTRACT
Objective: Assess efficacy of intermittent intravaginal metronidazole gel treatment in
reducing frequency of bacterial vaginosis (BV).
Design: Randomized, double-masked, placebo-controlled phase 3 trial.
Setting: Postnatal and family planning clinics of the Queen Elizabeth Central Hospital and two
health centers in Blantyre, Malawi.
Participants: Nonpregnant HIV-uninfected and -infected women.
Intervention: Intravaginal metronidazole treatment and placebo gels provided at baseline
and every 3 mo for 1 y.
Outcome measures: Primary: Cross-sectional and longitudinal comparisons of BV frequency
at baseline, 1 mo after product dispensation (post-treatment evaluation [PTE]), and every
quarterly visit. Secondary: Effect of treatment on BV clearance and recurrence.
Results: Baseline: 842 HIV-uninfected and 844 HIV-infected women were enrolled. The
frequency of BV at baseline in treatment and placebo arms, respectively, was 45.9% and 46.8%
among HIV-uninfected women, and 60.5% and 56.9% among HIV-infected women. Primary
outcomes: At the PTEs the prevalence of BV was consistently lower in treatment than placebo
arms irrespective of HIV status. The differences were statistically significant mainly in HIV-
uninfected women. Prevalence of BV was also reduced over time in both treatment and
placebo arms. In a multivariable analysis that controlled for other covariates, the effect of
intravaginal metronidazole treatment gel compared with placebo was not substantial: adjusted
relative risk (RR) 0.90, 95% confidence interval (CI) 0.83–0.97 in HIV-uninfected women and
adjusted RR 0.95, 95% CI 0.89–1.01 in HIV-infected women. Secondary outcomes: Intravaginal
metronidazole treatment gel significantly increased BV clearance (adjusted hazard ratio [HR]
1.34, 95% CI 1.07–1.67 among HIV-uninfected women and adjusted HR 1.29, 95% CI 1.06–1.58
among HIV-infected women) but was not associated with decreased BV recurrence. Safety: No
serious adverse events were related to use of intravaginal gels.
Conclusion: Intermittent microbicide treatment with intravaginal gels is an innovative
approach that can reduce the frequency of vaginal infections such as BV.
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PLoS CLINICAL TRIALSINTRODUCTION
Bacterial vaginosis (BV) is the most common vaginal
infection, and its impact on the health of women is substantial
[1–4]. The vaginal ecology is dynamic, where a Lactobacillus-
dominant ﬂora maintains an optimum acidic pH, which
suppresses BV-associated bacteria, and an elevated vaginal pH
facilitates growth of sexually transmitted organisms [5–8]. The
treatment of choice for BV is oral metronidazole. Another
treatment option is intravaginal metronidazole gel (0.75%)
[4]. Intravaginal therapy has minimal systemic effects and the
cure rates are comparable to the oral regimen [9].
We reported, in studies in Malawi, Africa, that disturbances
of vaginal ﬂora were common and associated with HIV-1
infection [10,11]. Identifying a simple treatment regimen for
these vaginal disturbances is a priority. Ideally, the treatment
of choice should be safe, easy to use, and effective over a long
period of time. Because earlier studies showed that only 11%
of women had a normal vaginal ﬂora [11], a presumptive
(mass) treatment approach would be practical. We therefore
decided on an approach in which all women were random-
ized to receive either an intravaginal antibiotic gel or an
intravaginal placebo gel. We opted to use intravaginal
metronidazole gel instead of oral metronidazole in this study
because oral metronidazole can cause gastrointestinal dis-
comfort and is difﬁcult to tolerate on repeated use [4].
Intravaginal metronidazole gel has a substantially lower dose
than oral metronidazole. An additional rationale for use of an
intravaginal antibiotic was to mimic other vaginal micro-
bicide studies that require daily use of the product, while in
this study use of a vaginal product is intermittent.
METHODS
Participants
Nonpregnant HIV-uninfected and -infected women were
recruited to this study from the postnatal care and family
planning clinics of the Queen Elizabeth Central Hospital, a
tertiary referral hospital, and two health centers in Blantyre,
Malawi. All women were counseled and gave consent prior to
enrollment. Inclusion criteria were: ability and willingness to
give written consent; nonpregnant; willingness to return for
follow-up visits; willingness to use the product as instructed;
willingness to provide specimens at each visit to test for
pregnancy and sexually transmitted infection (STI); and
residing in the study area. Exclusion criteria were: inability
to provide informed consent; pregnant; and refusal of any of
the enrollment inclusion requirements. Although use of
metronidazole during pregnancy is generally safe, adequate
data are not available on use of metronidazole gel during
pregnancy. Therefore, women who became pregnant during
this study had product use discontinued and were followed
throughout pregnancy. This clinical trial was approved by the
Johns Hopkins Bloomberg School of Public Health Commit-
tee on Human Research (Baltimore, Maryland, United States)
and the University of Malawi College of Medicine Research
and Ethics Committee (Blantyre, Malawi).
Interventions
A randomized, double-masked, placebo-controlled, presump-
tive-treatment, phase 3 clinical trial was conducted. Women
were enrolled at the ﬁrst (baseline) visit (V1.0) and returned
for follow-up visits quarterly, at 3, 6, 9, and 12 mo (V2.0, V3.0,
V4.0, and V5.0). Additional post-treatment evaluation (PTE)
visits occurred 1 mo after product dispensation, at 1, 4, 7, and
10 months (V1.9, V2.9, V3.9, and V4.9) (Figure 1).
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Editorial Commentary
Background: Bacterial vaginosis (BV) results from a change in the
normal balance of bacteria in the vaginal tract, and is very common. In
pregnant women, it is associated with poorer outcomes in pregnancy,
and is also linked with HIV transmission (although it is not certain that BV
actually increases the chance of getting HIV—just because these two
occur together it does not necessarily follow that one causes the other).
BV can be treated with metronidazole tablets, although these can cause
gut symptoms and should not be taken repeatedly. The researchers
wanted to carry out a multiclinic–based trial to find out whether a
metronidazole gel applied intermittently to the vagina (for five nights
every three months) would reduce the frequency of BV among women in
Malawi. HIV-infected and HIV-uninfected women, recruited from post-
natal and family planning clinics, were randomized to receive either
metronidazole gels, or equivalent placebo gels, every three months and
were then followed up for 12 months. The primary outcome for the trial
was the proportion of women with BV at each quarterly follow-up visit,
and the researchers intended to compare this outcome between
treatment arms at each visit and also to look at the overall changes over
time among women receiving either metronidazole or placebo, looking
separately at HIV-infected and HIV-uninfected women.
What this trial shows: In total 1,686 women took part in the trial (842
not infected with HIV, and 844 infected with HIV). The proportion of HIV-
uninfected women with BV dropped by around 20% over the course of
the trial, both in women using metronidazole and in those using
placebo. However, when comparing the proportion of HIV-uninfected
women with BV between the two arms of the trial, there did not seem to
be a consistent effect: differences were statistically significant at some
time points and not others. Among HIV-infected women, there was also
a drop over the course of the trial in the proportion of women with BV,
irrespective of whether they used metronidazole or placebo. Again,
when comparing the rate of BV among HIV-infected women between
study arms (metronidazole versus placebo), the researchers did not see a
consistent trend; differences were statistically significant at some time
points but not others. Overall, when comparing metronidazole and
placebo in an analysis that controlled for other factors, the metronida-
zole gel seemed to show a small effect in reduction of BV among HIV-
uninfected women, but no obvious effect among HIV-infected women.
Strengths and limitations: Strengths in the design of this trial include
the sample size, which was appropriate to detect an important effect of
the metronidazole gel (versus placebo) had one existed, and the
randomization and blinding procedures, which were designed to
minimize the chance that the trialists or women being enrolled could
anticipate to which arm of the trial they might be assigned. A key
limitation of this study, as the researchers acknowledge, is the absence
of a ‘‘no treatment’’ study arm. The frequency of BV dropped over the
course of the trial in women using the placebo gel, raising the possibility
that the placebo actually has some effect on bacteria in the vagina.
However, a trial with a ‘‘no treatment’’ arm would pose its own
problems, since trialists and participants would then not be fully blinded
as to their treatment status.
Contribution to the evidence: This trial adds data on the efficacy of
metronidazole gel when used intermittently, and among women in the
community who may or may not actually have BV. Previous studies have
evaluated treatment with metronidazole among women who already
have symptoms or a diagnosis of BV. The findings of this trial rule out a
substantial effect of metronidazole gel, as compared to placebo gel, in
reducing the frequency of BV in this setting.
The Editorial Commentary is written by PLoS staff, based on the reports of the
academic editors and peer reviewers.Study Products
We used metronidazole vaginal gel (0.75% MetroGel-Vaginal,
3M Pharmaceuticals, http://www.3M.com/pharma) buffered to
a pH of 4.0 in the treatment arm. Each gram of metronidazole
vaginal gel contained 7.5 mg of metronidazole and other
ingredients as speciﬁed by the manufacturer [12]. Each full
applicator delivers approximately 5 g of gel containing 37.5
mg of metronidazole in solution. The placebo gel was similar
to treatment gel but without the antibiotic metronidazole,
and is the same placebo that was used for the licensing studies
of the active gel. The placebo gel contained the same
excipients as the active gel, including preservatives such as
methyl and propyl parapens, as well as edetate disodium. It
also contained carbomer 934P, which has a buffering capacity
to maintain vaginal pH. Study products were used intra-
vaginally once a day (at bedtime) for ﬁve consecutive nights
every 3 mo. Participants were counseled in this study not to
wash the inside of the vagina until the following morning. At
each visit participants received one tube and ﬁve disposable
vaginal applicators. In total, four courses of product were
used during this trial.
Laboratory Procedures
HIV testing. Prior to enrollment, all women were provided
adequate pre- and post-test HIV counseling by trained
counselors. HIV testing was performed using either two
rapid HIV tests or conventional serologic tests [10]; con-
ﬁrmation with Western blot test was performed for all
discordant and new infections.
Diagnosis of BV. The Nugent scoring method (0–3 normal,
4–6 intermediate, and 7–10 BV) [13], based on Gram stained
vaginal smears, was used to diagnose BV at each visit.
Laboratory examination of the Gram stain slides was
performed at the Johns Hopkins University–College of
Medicine Research Laboratory in Blantyre, Malawi. For
quality control, a random sample of 300 slides was sent for
re-evaluation to a reference laboratory in the US (laboratory
of S. Hillier, Magee–Women’s Research Institute and the
University of Pittsburgh, Pittsburgh, Pennsylvania). Agree-
ment between the reference and local laboratory was
excellent (kappa 0.89; in the BV classiﬁcation the two
laboratories differed in only ﬁve slides; in these, the
variability was within two points of the Nugent score).
Figure 1. Study Profile
doi:10.1371/journal.pctr.0020010.g001
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Intermittent use of Intravaginal GelsConﬁrmation of pregnancy. A commercial kit to detect
hCG levels in urine (KAT Quick HCG, KAT Medical, http://
www.katmedical.com; the performance of this kit was
validated against another commercial kit, QuickVue, Quidel
Corporation, http://www.quidel.com) was used to screen for
pregnancy at enrollment and each visit. Women with positive
urine pregnancy tests were conﬁrmed by ultrasound.
Other laboratory tests. A vaginal wet mount was examined
microscopically at each visit to detect motile trichomonads
and candida using standard laboratory methods [10]. We did
not test for N. gonorrhoeae and C. trachomatis, because the
prevalence of these organisms has been very low (1%) in
recent studies in Malawi [14].
Study Questionnaires and Physical Examination
Demographic, clinical, acceptability, and adherence ques-
tionnaires were completed at enrollment and follow-up visits.
To monitor adherence, women were asked to return the
empty tube and used applicators at the PTE follow-up visits.
The amount of gel used in each tube was also assessed.
Adverse Experience Reporting
Trained clinicians and nurses conducted a speculum-aided
pelvic examination at each visit to detect mucosal abnormal-
ities.Adverseevents(AEs)byseverity(grade1,mild;2,moderate;
3, severe; 4, life threatening; and 5, death) and relatedness to
product use were recorded. Serious AEs were deﬁned based on
Code of Federal Regulations ICH Guidelines [15].
Objectives
The primary objective of this study was to determine whether
intermittent intravaginal metronidazole gel antibiotic treat-
ment would reduce the frequency of BV among HIV-
uninfected and -infected African women. We hypothesized
that repeated (intermittent) presumptive treatment with an
intravaginal antibiotic regimen would restore normal vaginal
ﬂora, enhance BV clearance (conversely, limit persistence),
and decrease BV recurrence.
Outcome Measures
The primary endpoint was proportion of women testing
positive for BV based on the Nugent score at each visit, both
cross-sectionally (between study arms) and longitudinally
(within study arms). The secondary outcome measure was the
effect of treatment on clearance and recurrence of BV.
Sample Size
In this trial a sample size of 832 HIV-uninfected women and
832 HIV-infected women was assumed adequate based on the
longitudinal comparisons to provide a power of 87% or more
to detect a reduction of 33% or more in the prevalence of BV
from a baseline prevalence of 30% (two treatment arms, type
1 error of a ¼ 0.05 and 10% loss during 1 y of follow-up).
Randomization
Block-randomized computer-generated lists were prepared in
the US and were stratiﬁed by clinic and HIV status. The study
product was provided to the site in a sealed envelope (opaque
and padded to avoid damage) with no identiﬁers other than
the study and clinic identiﬁcation numbers. These envelopes
were issued from a central pharmacy at the study site after
the women had been counseled and screened, and had given
their informed consent to enroll. The study pharmacist and
coordinator regularly carried out checks on the order of
randomization and matched enrollment identiﬁcation num-
bers with clinic and HIV status. The packaging and labeling of
the study product was performed in the US by an
independent team. Investigators, research workers, and
participants were masked about the study product. Neither
the study pharmacist at the research site in Malawi or study
coordinator was aware of the details of the study product.
Both treatment and placebo gels had comparable appear-
ance, consistency, and packaging. Participants were random-
ized at enrollment (baseline) visit (V1.0).
Statistical Methods
Data were checked for completeness and consistency and
entered locally in a database. All analyses of the primary
outcome were performed separately for HIV-uninfected and
-infected women using the intent to treat (rather than as
treated) approach. The proportion of events occurring in the
two study arms were cross-sectionally compared at each visit.
Analyses were also conducted to compare events longitudi-
nally within the same study arms between visits. Chi-square
(exact test) and other nonparametric tests were used for these
comparisons. Generalized estimating equation log binomial
models based on relative risk ratio assessed longitudinal
associations of treatment with BV after controlling for other
covariates measured at multiple visits to account for repeated
visit correlation of these repeated observations. Univariable
(unadjusted) relative risks (RRs) and adjusted RRs, and 95%
conﬁdence intervals (CIs) are presented. Statistical signiﬁ-
cance was considered to be two-sided p   0.05.
We further analyzed BV clearance and recurrence in the
subgroups of women to determine the impact of intravaginal
antibiotic treatment among HIV-uninfected and -infected
women. We deﬁned BV clearance as a positive BV test at
baseline with a negative BV test (ﬁrst negative test) in a follow-
up visit, and BV recurrence as a positive BV test at baseline
with a negative BV test (ﬁrst negative test) in a follow-up visit
and becoming BV positive (ﬁrst positive test) in a subsequent
visit. We used Kaplan-Meier survival analyses to estimate
median time to clearance and recurrence events and the
cumulative probability of these events stratiﬁed by study arm
among HIV-uninfected and -infected women. Cox propor-
tional hazard models were used to control for various factors
and determine the major predictors of these events. Treat-
ment, number of sex partners, frequency of sex, vaginal pH,
douching, and T. vaginalis were included in these Cox models
(all were time-dependent except for treatment). Statistical
signiﬁcance was determined by a p-value   0.05. All analyses
were conducted using SAS (version 8.2; http://www.sas.com).
Study Monitoring
This study was monitored by a ﬁve-member Data and Safety
Monitoring Board. Study conduct and review of clinical AEs
were also monitored by two independent monitors.
Provision of Clinical Care
Routine clinical care for all women (including continuous
counseling, provision of condoms, and treatment of STIs) was
provided by the project at no cost. HIV-infected women were
provided additional support by trained counselors and
community educators. Specialized clinical care for HIV-
infected women was provided by project clinicians and
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Intermittent use of Intravaginal Gelsincluded referral for antiretroviral treatment in a clinic
within the Queen Elizabeth Central Hospital in Blantyre.
RESULTS
Recruitment
This study was conducted from January 2003 through May
2005. Overall, 3,238 women were screened for this study; of
these 1,686 (52.1%) were enrolled: 842 HIV-uninfected and
844 infected women. Of the women screened, 796 (24.6%)
were ineligible based on the exclusion criteria and 756
(23.3%) did not consent for HIV testing or did not return to
receive their HIV test results.
Participant Flow
Women who enrolled were equally randomized to each of
treatment or placebo arms (Figure 1). Among both HIV-
uninfected and -infected women, the proportions discon-
tinued due to pregnancy or lost to follow-up for other
reasons occurred comparably between treatment and placebo
and were not signiﬁcantly different (unpublished data). For
women who did not complete study visits, all data available
prior to discontinuation were included in the analysis.
Baseline data. Baseline sociodemographic and behavioral
characteristics were similar in the two study arms both among
HIV-uninfected and -infected women (Table 1). There were
also no statistically signiﬁcant differences in baseline charac-
teristics of women who completed the study and those who
did not (terminated, died, or lost; unpublished data).
Primary Outcomes
Univariable results for HIV-uninfected women. The visit-
speciﬁc proportions of women with BV and normal vaginal
ﬂora among HIV-uninfected women are shown in Table 2. The
prevalence of BV at the enrollment visit (V1.0) was similar in
treatment(45.9%)andplacebo(46.8%).Atthequarterlyfollow-
up visits (V2.0, V3.0, and V4.0), the prevalence of BV was
consistently lower in treatment versus placebo; these differ-
ences, however, were not statistically signiﬁcant except at V2.0
(p¼0.05).TheprevalenceofBVdroppedovertimeinbotharms
compared to baseline to 24.7% in treatment (a drop of 21.2%)
andto28.8%inplacebo(adropof18.0%)atthelastvisit(V5.0);
p,0.001(McNemar’sdiscordantpairs).AtthePTEvisits(V1.9,
V2.9, V3.9, and V4.9), the prevalence of BV was consistently
lower in treatment than placebo and the differences were
statistically signiﬁcant at each follow-up visit (with the
exception of V4.9, p¼0.09). The prevalence of normal vaginal
ﬂora in treatment was lowest at baseline (V1.0), increased in
subsequent visits, and became sustained with a prevalence of
over 50% for visits after 6 mo (after V3.0) in quarterly and PTE
visits.Therewerealsosimilarincreasesinprevalenceofnormal
ﬂora in placebo over time; however, the proportion of women
with normal ﬂora was always less in the placebo compared to
visit-speciﬁc proportions in the treatment arm for both
quarterly and PTE visits. The differences in prevalence of
normalvaginalﬂorabetweentreatmentandplaceboarmswere
not statistically signiﬁcant beyond the ﬁrst initial visits.
Univariable results for HIV-infected women. Table 3 shows
visit-speciﬁc proportions of women with BV and normal
vaginal ﬂora among HIV-infected women. The prevalence of
BV was not statistically different between the two study arms
at baseline (although it was higher for HIV-infected than for
HIV-uninfected women) and likewise in subsequent quarterly
visits. There were signiﬁcant (p , 0.001, McNemar’s test)
declines in BV prevalence from baseline to V5.0 in both study
arms (a drop of 10.9% in treatment and 12.7% in placebo). In
follow-up PTE visits, BV was lower in treatment than placebo,
but the differences were not statistically signiﬁcant in the ﬁrst
two PTE visits (V1.9 and V2.9) and became signiﬁcant in the
.......................................................................................................................................................................................
Table 1. Comparison of Baseline Characteristics among HIV-Uninfected and -Infected Women by Study Arm
Characteristic Group HIV Uninfected HIV Infected
Treatment,
%( n)
Placebo,
%( n)
p-Value Treatment,
%( n)
Placebo,
%( n)
p-Value
a
Age (years) ,25 48.2 (203/421) 45.4 (191/421) 0.04 36.3 (153/422) 35.6 (150/422) 0.98
25–34 39.9 (168/421) 36.6 (154/421) 52.1 (220/422) 52.8 (223/422)
35þ 11.9 (50/421) 18.1 (76/421) 11.6 (49/422) 11.6 (49/422)
Education No schooling 9.3 (39/421) 14.3 (60/421) 0.06 12.3 (52/422) 8.8 (37/421) 0.25
Grade 1–8 59.9 (252/421) 59.1 (249/421) 58.3 (246/422) 61.3 (258/421)
Form 1–4 or higher 30.9 (130/421) 26.6 (112/421) 29.4 (124/422) 29.9 (126/421)
Married/living with partner 93.8 (395/421) 95.3 (401/421) 0.45 92.6 (389/420) 88.6 (372/420) 0.06
Parity 0 — — 0.80 0.7 (3/422) 0.5 (2/422) 0.30
1 19.5 (82/421) 18.3 (77/421) 13.7 (58/422) 10.2 (43/422)
2 25.7 (108/421) 27.6 (116/421) 25.4 (107/422) 23.9 (101/422)
3þ 54.9 (231/421) 54.2 (228/421) 60.2 (254/422) 65.4 (276/422)
Number of lifetime sexual partners 1 39.4 (166/421) 41.6 (175/421) 0.31 15.4 (65/422) 15.2 (64/421) 0.38
2 30.4 (128/421) 33.0 (139/421) 30.1 (127/422) 34.4 (145/421)
3þ 30.2 (127/421) 25.4 (107/421) 54.5 (230/422) 50.4 (212/421)
Frequency of sex per week in last 3 mo 0 4.5 (19/419) 3.3 (14/421) 0.77 4.3 (18/422) 5.5 (23/421) 0.17
1 19.6 (82/419) 20.7 (86/421) 23.9 (101/422) 29.9 (126/421)
2 29.4 (123/419) 28.0 (118/421) 31.5 (133/422) 28.0 (118/421)
3þ 46.5 (195/419) 48.0 (202/421) 40.3 (170/422) 36.6 (154/421)
Douching .13 per day in last 3 mo 72.1 (300/416) 71.2 (297/417) 0.82 71.5 (299/418) 71.4 (299/419) 1.00
Use any family planning method
b 76.5 (322/421) 79.1 (333/421) 0.41 65.2 (275/422) 66.4 (280/422) 0.77
av
2 test for proportions.
bOverall use among HIV-uninfected 77.8% and among HIV-infected 65.8%; p , 0.0001.
doi:10.1371/journal.pctr.0020010.t001 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Intermittent use of Intravaginal Gelslast two PTE visits (V3.9 and V4.9). There were no statistically
signiﬁcant differences in prevalence of normal ﬂora at the
quarterly or PTE visits between treatment and placebo
(except V3.9 of PTE). The increase in prevalence of normal
ﬂora over time in HIV-infected women was modest compared
to the increase in HIV-uninfected women.
Multivariable results. The effect of intermittent intra-
vaginal metronidazole gel treatment on BV, compared to the
placebo intravaginal gel, was modest in multivariable analyses
that controlled for other covariates (Table 4). Among HIV-
uninfected women, intravaginal metronidazole treatment
signiﬁcantly reduced the risk of BV after controlling for
age, T. vaginalis infection, vaginal pH level, and baseline BV
(adjusted RR 0.90; 95% CI 0.83–0.97). Among HIV-infected
women, the association of treatment with BV was of border-
line signiﬁcance (adjusted RR 0.95; 95% CI 0.89–1.01). In both
HIV-uninfected and -infected women, there were signiﬁcant
associations of BV with the covariates Trichomonas, vaginal
pH, and BV at baseline. Detection of Trichomonas and baseline
BV was associated with signiﬁcantly higher risk of BV, while
lower vaginal pH was signiﬁcantly associated with reduced
risk of BV (Table 4).
Secondary Outcomes
Clearance of BV. Among 387 HIV-uninfected women who
had BV at baseline, 325 cleared BV (165 of 192 in treatment
and 160 of 195 in placebo arm). Among 486 HIV-infected
women who had BV at baseline 391 cleared BV (209 of 251 in
treatment and 182 of 235 in placebo arm). The cumulative
probability of BV clearance stratiﬁed by study arm in HIV-
uninfected and -infected women is shown in Figure 2. In both
HIV-uninfected and infected women, the median time to BV
clearance among women who had BV at baseline was
signiﬁcantly shorter among those who received metronida-
zole gel than in those who received placebo gel. For example,
among HIV-uninfected women the median of BV clearance
in treatment was 92 d compared to 125 d in placebo (p ¼
0.008; log rank test) and among HIV-infected women the
median of clearance in treatment was 93 d compared to 123 d
in placebo (p ¼ 0.03; log rank test). At 3 mo, the cumulative
probability of BV clearance among HIV-uninfected women
was 49.6% in treatment arm compared to 33.6% in placebo
arm, and among HIV-infected women the cumulative
probabilities of clearance were similar, 48.6% and 34.8%,
respectively. Among both HIV-uninfected and -infected
women, treatment with intravaginal metronidazole and lower
.......................................................................................................................................................................................
Table 3. Prevalence of BV and Normal Vaginal Flora by Study Arm among HIV-Infected Women
Visit
Category
Visit
Number
Treatment %
BV (N)
Placebo %
BV (N)
p-Value
a Treatment %
Normal Flora (N)
Placebo %
Normal Flora (N)
p-Value
a
Quarterly visits
b V1.0 60.5 (415) 56.9 (413) 0.32 23.1 (415) 25.2 (413) 0.52
V2.0 54.4 (366) 52.4 (361) 0.60 25.1 (366) 28.5 (361) 0.32
V3.0 52.4 (330) 45.1 (344) 0.06 28.8 (330) 29.9 (344) 0.80
V4.0 39.1 (294) 44.4 (297) 0.21 35.4 (294) 34.0 (297) 0.73
V5.0
c 49.6 (278) 44.2 (269) 0.23 31.3 (278) 33.8 (269) 0.58
V1.9 47.5 (402) 51.9 (397) 0.23 26.1 (402) 24.9 (397) 0.75
PTE visits
d V2.9 38.6 (342) 44.2 (337) 0.14 35.0 (342) 28.9 (337) 0.08
V3.9 35.9 (315) 45.5 (314) 0.01 37.1 (315) 29.3 (314) 0.04
V4.9 35.7 (264) 44.2 (276) 0.05 40.2 (264) 34.8 (276) 0.21
Women with intermediate Nugent score are excluded (therefore, % BV and % normal flora in each study arm do not add up to 100%).
aBased on exact test, comparing treatment versus placebo.
bTreatment or placebo gel issued at these visits.
cNo product issued at this visit.
dVisits conducted one month after application of product.
doi:10.1371/journal.pctr.0020010.t003 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
.......................................................................................................................................................................................
Table 2. Prevalence of BV and Normal Vaginal Flora by Study Arm among HIV-Uninfected Women
Visit
Category
Visit
Number
Treatment %
BV (N)
Placebo %
BV (N)
p-Value
a Treatment %
Normal Flora (N)
Placebo %
Normal Flora (N)
p-Value
a
Quarterly visits
b V1.0 45.9 (418) 46.8 (417) 0.84 36.8 (418) 36.0 (417) 0.83
V2.0 38.4 (365) 45.7 (363) 0.05 41.6 (365) 32.8 (363) 0.01
V3.0 34.4 (320) 36.7 (324) 0.56 43.4 (320) 41.1 (324) 0.58
V4.0 22.4 (277) 27.8 (284) 0.15 54.1 (277) 50.4 (284) 0.40
V5.0
c 24.7 (275) 28.8 (285) 0.29 56.4 (275) 51.2 (285) 0.24
PTE visits
d V1.9 35.0 (389) 48.7 (394) ,0.0001 42.9 (389) 31.5 (394) 0.001
V2.9 28.0 (336) 37.6 (327) 0.01 46.7 (336) 39.5 (327) 0.06
V3.9 23.6 (292) 32.7 (297) 0.02 50.7 (292) 44.1 (297) 0.12
V4.9 23.6 (250) 30.4 (253) 0.09 58.0 (250) 52.2 (253) 0.21
Women with intermediate Nugent score are excluded (therefore, % BV and % normal flora in each study arm do not add up to 100%).
aBased on exact test, comparing treatment versus placebo.
bTreatment or placebo gel issued at these visits.
cNo product issued at this visit.
dVisits conducted one month after application of product.
doi:10.1371/journal.pctr.0020010.t002 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Intermittent use of Intravaginal Gelsvaginal pH were signiﬁcantly associated with increased BV
clearance after adjusting for other risk factors (Table 5). On
the other hand, Trichomonas infection and multiple sex
partners in HIV-uninfected women were signiﬁcantly asso-
ciated with decreased BV clearance. Vaginal douching and
frequency of sex were not associated with BV clearance after
adjusting for other factors.
Recurrence of BV. We also examined the effect of intra-
vaginal metronidazole gel treatment on BV recurrence among
381 HIV-uninfected and 409 HIV-infected women who had
BV at baseline and then cleared BV. Overall, 196 HIV-
uninfected women (92 in treatment and 104 in placebo) and
301 HIV-infected women (166 in treatment and 135 in
placebo) developed BV recurrence. The cumulative proba-
bility of BV recurrence stratiﬁed by study arm in HIV-
uninfected and infected women is shown in Figure 2. There
were no statistically signiﬁcant differences in median time to
BV recurrence between study treatment arms among both
HIV-uninfected and -infected women. Among HIV-unin-
fected women the median time to BV recurrence was 274 d
in treatment and 178 d in placebo (p ¼ 0.21) and among HIV
infected women 92 d in treatment and 95 d in placebo (p ¼
0.53). However, the overall median time to BV recurrence in
HIV-uninfected women was signiﬁcantly longer than in HIV-
infected women (210 d versus 93 d; p , 0.0001, log-rank test).
Among HIV-uninfected women the cumulative probability of
BV recurrence at 3 mo was 32.9% in treatment arm and 37.9%
in placebo arm. Among HIV-infected women the probability
of recurrence at 3 mo was 47.1% in the treatment arm and
46.2% in the placebo arm. Among both HIV-uninfected and
-infected women, treatment was not signiﬁcantly associated
with lower BV recurrence. However, low vaginal pH signiﬁ-
cantly decreased BV recurrence, and vaginal douching
signiﬁcantly increased the risk of BV recurrence, after
controlling for treatment and other factors (Table 6). Multiple
sex partners and frequency of sex were not associated with
recurrence of BV after controlling for other factors.
Adherence and Adverse Events
In this trial, among all women, nonadherence (based on
proportion of women who did not return the used tube or
used less than 1/3 of the gel in each tube) ranged from 3% to
7% throughout the study and was similar in each study arm.
Similarly, acceptability was high (.90%) and was not differ-
ent in each study arm. There were no statistically signiﬁcant
differences in reported acceptability responses at the last visit
prior to loss or discontinuation among women who com-
pleted or did not complete the study. There were no serious
AEs related to the study product. Among HIV-uninfected
women four cases of grade 3 or grade 4 AEs were reported;
three in treatment and one in placebo (only one case of
symptomatic candidiasis in the treatment arm was considered
treatment related). Among HIV-infected women, 28 grade 3
or 4 AEs were reported (17 in the treatment and 11 in the
placebo arm; only one case of vulval allergic reaction in the
treatment arm was considered related). There were no
differences in rates of symptomatic (reported) candida by
study arm among HIV-uninfected or -infected women (range
0.5%–5.0%). The frequency of laboratory-conﬁrmed candida
infections remained stable in each study arm with minimal
ﬂuctuation during study (range 14%–25% in HIV-uninfected
women and 18%–29% in infected women).
DISCUSSION
Interpretation
The concept of intermittent application of intravaginal
products such as a vaginal microbicide is innovative. Non-
vaginal intermittent presumptive treatment of STIs has been
used in large community-based trials [16]. In this study
intermittent treatment with metronidazole gel reduced BV
when compared with placebo at the cross-sectional visits or
compared longitudinally with baseline frequency. These
declines were especially consistent among HIV-uninfected
women (Table 2); among HIV-infected women the declines in
BV prevalence were less substantial (Table 3). There were also
very signiﬁcant declines from baseline in frequency of BV
with placebo, suggesting that the placebo gel may have had a
microbicidal effect. It is likely that the placebo, similar to the
treatment, may have changed the vaginal environment as a
lubricant or chemical barrier. Therefore declines in preva-
lence of BV with metronidazole gel treatment in this study
were in addition to any beneﬁcial effects of placebo.
Among HIV-uninfected women, treatment was associated
with a progressive increase in normal vaginal ﬂora (Table 2),
suggesting restoration and maintenance of normal vaginal
ﬂora. Among HIV-infected women there was no increase in
normal ﬂora (Table 3), possibly due to a weaker immune
response, inability to restore vaginal ﬂora, or more persis-
tence of BV [17]. In multivariable analysis (after controlling
for BV at baseline because it is a predictor of subsequent BV
infection), Trichomonas infection increased the risk of BV while
lower vaginal pH was associated with lower risk of BV (Table
4). These ﬁndings are consistent with vaginal pH patterns in
.......................................................................................................................................................................................
Table 4. Association of BV with intermittent treatment among HIV-uninfected and infected women
Factor HIV-Uninfected HIV-Infected
Univariable RR (95% CI) Adjusted RR (95% CI) Univariable RR (95% CI) Adjusted RR (95% CI)
Treatment versus placebo 0.84 (0.75–0.94) 0.90 (0.83–0.97) 0.97 (0.89–1.06) 0.95 (0.89–1.01)
Age ,25 versus  25 1.00 (0.89–1.12) 1.00 (0.92–1.09) 1.09 (1.00–1.20) 1.05 (0.98–1.12)
T. vaginalis detected
a 1.51 (1.32–1.73) 1.24 (1.10–1.39) 1.36 (1.24–1.48) 1.22 (1.13–1.32)
Vaginal pH (,4.5 versus  4.5)
a 0.54 (0.49–0.59) 0.55 (0.50–0.61) 0.62 (0.57–0.67) 0.64 (0.59–0.70)
BV at enrollment 2.99 (2.66–3.37) 2.73 (2.43–3.07) 2.46 (2.21–2.73) 2.27 (2.05–2.52)
aAt each visit.
doi:10.1371/journal.pctr.0020010.t004 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Intermittent use of Intravaginal GelsFigure 2. Probability of BV Clearance and Recurrence
(A and B) Clearance in HIV-uninfected (A) and -infected (B) women.
(C and D) Recurrence in HIV-uninfected (C) and -infected (D) women.
doi:10.1371/journal.pctr.0020010.g002
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Intermittent use of Intravaginal Gelswhich T. vaginalis and BV organisms favor a higher (.4.5)
vaginal pH while other organisms such as candida species
favor a lower (4.0–4.5) vaginal pH [7,18]. As reported by others
[19,20], the frequency of candida was higher among women
who used metronidazole gel, but most of these women were
asymptomatic. Treating BV-associated bacteria may also allow
other organisms such as candida species to predominate [21].
Examination of BV prevalence pattern in Tables 2 and 3
shows that there was a decrease in BV prevalence following
each act of intravaginal gel application (PTE visits) that was
followed by an increase at each subsequent quarterly visit
(e.g., in Table 2 in the treatment arm BV prevalence increased
from 35.0% at V1.9 to 38.4% at V2.0 and from 28.0% at V2.9
to 34.4% at V3.0). This suggests either BV recurrence or
persistence (i.e., inadequate clearance of BV). Our ﬁndings
suggest that metronidazole intravaginal gel, compared to
placebo, was more effective at clearing BV than preventing
recurrences. For example, after controlling for several
factors, treatment with metronidazole gel in both HIV-
uninfected and HIV-infected women was signiﬁcantly asso-
ciated with BV clearance (Table 5) but not with BV
recurrence (Table 6). Among both HIV-uninfected and
-infected women the median time to clearance of BV was
about three months with metronidazole gel and about four
months with placebo gel (p , 0.05). The median times for
recurrence were not different by study arm (albeit signiﬁ-
cantly shorter among HIV-infected [;3 mo] compared to
uninfected women [;7 mo]). Vaginal douching was not
associated with BV clearance but signiﬁcantly increased
recurrence. It is likely that BV clearance was not inﬂuenced
by vaginal douching, because women were advised not to
douche after application of the intravaginal gel. Because
douching is a common practice in this population (;70%
reported douching at baseline), women would have resumed
regular douching after completion of gel use, enhancing BV
recurrence, possibly through changes in vaginal ﬂora [22].
The lack of a study arm that did not use an intravaginal gel
as a control arm is a limitation of this study, as an estimate of
true efﬁcacy of the metronidazole intravaginal treatment gel
would have required use of no product. This is a challenging
aspect of almost all microbicide trial designs [23]. As shown in
Table 4 the overall estimate of efﬁcacy of treatment gel
compared to placebo gel was modest. Use of an arm with no
intravaginal gel, however, would have weakened the study
design due to nonmasking, possible dilution of estimated
effect (due to potential contamination), and poor retention.
The alternative design of using intermittent oral metronida-
zole tablets as a comparison arm also has limitations such as
nonmasking. Other factors, such as changes in behavior for
being in the study, should also be considered for the
substantial BV reductions (Hawthorne effect). It is unlikely,
however, that the temporal effect of any counseling and
clinical services provided during this study has been differ-
ential, because these services were for all women and the study
personnel were masked. The most plausible explanation for
the similar trends in BV reduction in both arms of this study is
the inherent activity of the placebo formulation. Despite
metronidazole intravaginal gel being more effective, its true
efﬁcacy is underestimated in this study due to the residual
effect of the placebo gel. Finding a universal ‘‘inert’’ placebo
vaginal gel remains a priority for microbicide research.
The results of this study are unlikely to be inﬂuenced by
losses of women during follow-up. The losses in each study
arm were comparable and there were no differences in
.......................................................................................................................................................................................
Table 5. Factors Associated with BV Clearance
Factor HIV Uninfected HIV Infected
Adjusted HR (95% CI) Crude HR (95% CI) Adjusted HR (95% CI) Crude HR (95% CI)
Treatment versus placebo 1.34 (1.07–1.67) 1.34 (1.08–1.67) 1.29 (1.06–1.58) 1.25 (1.02–1.52)
Vaginal pH ,4.5 versus  4.5 2.34 (1.84–3.00) 2.31 (1.88–3.05) 2.20 (1.74–2.78) 2.21 (1.75–2.79)
T. vaginalis yes versus no 0.37 (0.20–0.68) 0.37 (0.20–0.67) 0.70 (0.47–1.04) 0.67 (0.45–0.99)
Vaginal douching yes versus no 1.16 (0.90–1.51) 1.10 (0.85–1.42) 1.03 (0.83–1.29) 1.04 (0.83–1.30)
Multiple sex partners, continuous variable 0.36 (0.18–0.71) 0.44 (0.23–0.84) 0.97 (0.80–1.17) 0.96 (0.80–1.15)
Frequency of sex, continuous variable 1.01 (0.95–1.07) 0.98 (0.92–1.04) 1.00 (0.95–1.05) 1.00 (0.95–1.06)
Data were obtained through Cox proportional hazards models.
doi:10.1371/journal.pctr.0020010.t005 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
.......................................................................................................................................................................................
Table 6. Factors Associated with BV Recurrence
Factor HIV Uninfected HIV Infected
Adjusted HR (95% CI) Crude HR (95% CI) Adjusted HR (95% CI) Crude HR (95% CI)
Treatment versus placebo 0.94 (0.71–1.24) 0.90 (0.68–1.19) 1.12 (0.89–1.41) 1.16 (0.92–1.45)
Vaginal pH ,4.5 versus  4.5 0.30 (0.20–0.44) 0.30 (0.20–0.45) 0.53 (0.38–0.73) 0.52 (0.38–0.75)
T. vaginalis yes versus no 1.42 (0.72–2.80) 1.68 (0.86–3.30) 1.31 (0.80–2.41) 1.41 (0.86–2.30)
Vaginal douching yes versus no 1.41 (1.00–1.99) 1.35 (0.96–1.90) 1.31 (0.99–1.74) 1.34 (1.01–1.78)
Multiple sex partners, continuous variable 1.11 (0.79–1.58) 1.09 (0.74–1.62) 0.74 (0.47–1.187) 0.73 (0.46–1.15)
Frequency of sex, continuous variable 0.99 (0.91–1.08) 0.94 (0.85–1.04) 1.01 (0.93–1.09) 0.91 (0.84–1.01)
Data were obtained through Cox proportional hazards models.
doi:10.1371/journal.pctr.0020010.t006 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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demographic and acceptability characteristics of women who
completed or did not complete the study. Additionally, the
efﬁcacy of treatment was established by both cross-sectional
and longitudinal analyses when losses were minimal at earlier
visits. In this study, we note that a comparable proportion of
HIV-infected and -uninfected women became pregnant.
Other studies in sub-Saharan Africa, however, reported lower
rates of pregnancy among HIV-infected women due to
biological factors limiting fertility in HIV-infected women
such as failure to conceive and increased pregnancy losses
[24]. Further analysis of our data suggests that multiple
factors may have contributed to the comparability of
pregnancy rates among HIV-infected and -uninfected wom-
en. For example, over 70% of the HIV-uninfected women
were using a family planning method (Table 1), prevalence of
use was signiﬁcantly higher among HIV-uninfected compared
to -infected women (p , 0.0001), and additionally, HIV
infected women who became pregnant were younger, health-
ier, wanted a pregnancy sooner, and used a family planning
method less (unpublished data). We did not assess drug
resistance during this intermittent use of the product.
Available data are reassuring and suggest that metronidazole
is highly active despite its widespread use and development of
resistance is rare [25].
Intermittent use of intravaginal gels should be considered
for treatment of vaginal infections. These gels could modify
the vaginal milieu, coat vaginal surfaces and potentially
prevent attachment of pathogenic organisms to appropriate
receptors, and/or physically reduce itching and accompany-
ing trauma inside the vagina or on the vulval surface. Vaginal
products, mostly traditional agents, are extensively used in
sub-Saharan Africa [26]. Therefore, intermittent use of
vaginal gels would be culturally acceptable.
Generalizability
The ﬁndings of this study can be applied to other populations
in Africa. Despite the exclusions we made in this trial as
required in the protocol, women enrolled had important
characteristics comparable to other populations in Malawi
and sub-Saharan Africa, thus enhancing external validity. For
example, HIV prevalence among women enrolled in this
study was around 26% (similar to HIV prevalence estimates
in the antenatal/postnatal clinics in urban Malawi [27]) and
BV prevalence in this study was similar to others reported
from Uganda and South Africa [1,2].
Overall Evidence
BV is a common condition with a poorly understood etiology
[28]. It is not recognized as a typical STI despite being
inﬂuenced by multiple underlying risk factors that are
characteristic of conventional STIs. Likewise, its treatment
and prevention remain difﬁcult. We conducted a web-based
PubMed (http://www.pubmed.gov) literature search focusing
on treatment of BV in nonpregnant women to compare with
ﬁndings from our current trial. In a review article of BV
treatment options in nonpregnant women, Joesoef and
colleagues recommended oral metronidazole (500 mg twice
daily for 7 d), clindamycin vaginal cream (2% once daily for 7
d),ormetronidazolevaginalgel(0.75%twicedailyfor5d)[29].
Subsequent to this review, a randomized prospective study
conducted in the US reported no differences in efﬁcacy or
safety between once-daily or twice-daily BV treatment for ﬁve
consecutive days with 0.75% metronidazole intravaginal gel
[20]. Comparison of intravaginal and oral metronidazole
treatment regimens also showed no differences in efﬁcacy by
mode of administration; however, women receiving oral
metronidazole are more likely to experience gastrointestinal
sideeffects,althoughoralmedicationmaybemoreconvenient
[29].Weoptedto usea once-daily intravaginal regimenforﬁve
days to simplify the regimen and maximize adherence. We also
preferred a topical application instead of oral medication
because of our interest in vaginal microbicides and assessment
of the intermittent regimen in an African setting where
adherence with a daily application of an effective vaginal
microbicidecouldbeachallenge.Theﬁndingsofthisstudyare
in agreement with available literature on the efﬁcacy of
treatmentofBVusingintravaginalmetronidazolegel[29].The
longitudinal efﬁcacy estimates of intravaginal metronidazole
gel in our study were lower than estimates reported from US
studies because we followed a presumptive treatment ap-
proach and did not limit enrollment to symptomatic or BV-
established women as has been the approach in other studies
[29]. Recurrence of BV is a limitation of existing regimens, and
recent data suggest that a more aggressive and extended
treatment is needed to manage BV recurrences [30]. Our study
is unique in assessing the concept of intermittent intravaginal
gel and for evaluating this regimen among both HIV-
uninfected and HIV-infected African women.
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